CAR T cell News and Research

RSS

Preclinical study unlocks the promise of CAR T-cell therapy for treatment of solid tumors

Scientists at St. Jude Children's Research Hospital identified a molecular mechanism that in a preclinical study unlocked the promise of CAR T–cell therapy for treatment of solid tumors.

22 Jun 2022

New screening tool could increase the number of tests on solid tumor sample by up to 50 times

A screening tool developed at the University of Strathclyde, UK, could increase the number of tests on a solid tumor sample by up to 50 times.

21 Jun 2022

Creating CAR T cells without an immune brake

T cells are usually very good at eliminating diseased cells. But they seem to fail when it comes to tumor cells.

10 Jun 2022

Intestinal microbiome may contribute to the pathogenesis of MSI colon cancers, study suggests

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey's only National Cancer Institute- Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable (MSI) tumors.

19 May 2022

Novel method could bring life-saving benefits of CAR T-cell therapy to patients with acute myeloid leukemia

Massachusetts General Hospital researchers have developed a novel treatment strategy that has the potential to bring the life-saving benefits of chimeric antigen receptor T-cell therapy (CAR T) to patients with acute myeloid leukemia (AML) the most common form of leukemia in adults.

28 Apr 2022

Roswell Park experts to share latest advances in the treatment of blood-related cancers

Roswell Park Comprehensive Cancer Center specialists will share the latest advances and developments in the treatment of blood-related cancers at the 2022 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah, from April 23 to 26.

26 Apr 2022

CAR T-Cell Therapy: The Future of Cancer and HIV Treatment?

In this interview, News-Medical speaks to Professor Jun Huang about CAR T-cell therapy and its future as a potential treatment for cancer or HIV.

20 Apr 2022

Researchers identify certain gene regulation signatures in CAR T-resistant leukemia patients

Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the AACR Annual Meeting 2022, held April 8-13.

13 Apr 2022

Preliminary data from clinical trial reveals safety, efficacy of new CAR T-cell therapy for solid tumors

A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Most cancer patients develop antibodies after receiving COVID-19 vaccine, study shows

Cancer patients who have compromised immune systems due to their disease or therapy remain at high risk for COVID-19 infection.

10 Mar 2022

Researchers develop new precision medicine technology for cancer immunotherapy

In recent years, great advances have been made in the development of new successful immunotherapies to treat cancer. CAR T-cell therapy and antibody treatments are two types of targeted immunotherapies that have revolutionized areas of cancer care.

28 Feb 2022

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.

2 Feb 2022

Study provides a new treatment option for patients with relapsed B-cell lymphoma

A new therapy showed improvement over the standard treatment for relapsed B-cell lymphoma, according to a study published in the New England Journal of Medicine.

26 Jan 2022

Study provides a more effective treatment approach to preventing graft-versus-host-disease

A new study led by UC Davis Health researchers showed that blocking IL-6 and TNF cytokines provides a more effective approach to preventing life-threatening graft-versus-host-disease (GVHD), an inflammatory condition that develops in patients after their allogeneic hematopoietic stem cell transplantation (allo-HSCT).

16 Dec 2021

Study offers new hope for large B-cell lymphoma patients

Of the 18,000 people diagnosed with large B-cell lymphoma each year, only half will be successfully treated with chemotherapy. The 9,000 remaining patients typically have poor outcomes, with only 25% responding to additional, higher-intensity chemotherapy, followed by a stem cell transplant.

13 Dec 2021

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

24 Nov 2021

CAR-T cell treatment's efficacy in hematological malignancies predicted by epigenetics

One in five cancers affects blood cells and lymph nodes, causing leukemias and lymphomas, respectively. Although their treatment with drugs has led to a great advance in their cure, there are cases where there is no clinical response or resistance to them is generated.

21 Oct 2021

New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia

A retrospective study led by Northwestern Medicine investigators found that the chimeric antigen receptor (CAR) T-cell immunotherapy drug tisagenlecleucel demonstrated safety and efficacy in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia (B-cell ALL), even when the drug doesn't meet the FDA's strict manufacturing standards.

19 Oct 2021

Newly developed gel helps improve the effectiveness of immunotherapy in glioblastoma

Pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma, a highly malignant and deadly cancer, improved the immunotherapy's effectiveness, report researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and colleagues. The findings appeared on Oct. 6, 2021, in Science Advances.

7 Oct 2021

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

A new study published on the medRxiv* preprint server focused on a patient with a persistent symptomatic viral infection for over a year. Researchers amplified sub-genomic transcripts for the E gene (sgE) using nasopharyngeal samples of the patient infected with SARS-CoV-2 over the course of 335 days.

6 Oct 2021